Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by progressive joint destruction associated with extra-articular manifestations affecting different internal organs [1] [2].

RA is the most common chronic inflammatory joint disease and occurs throughout the world, in all ethnic groups, with a prevalence that ranges from 0.3% to 1.2% [2].

RA is associated with increasing of cardiovascular (CV) morbidity and mortality due to accelerated atherosclerosis. Thus, there is evidence of close relationship between RA and CV events such as stroke, congestive heart-failure and myocardial infarction [1] [3] - [16].

Several studies showed also the increasing of the prevalence of subclinical atherosclerosis, using different modalities including carotid ultrasound to detect carotid plaques.

Subclinical atherosclerosis may additionally identify the patients with high risk of CV events [17].

The high incidence of CV morbidity and mortality may due to higher prevalence of traditional cardiovascular risk factors and the role of systemic inflammation [11].

However, there are paucity data about CV risk and RA in sub-Saharan Africa [10] [18].

We conducted a cross sectional study in Senegalese patients with RA to assess the prevalence of cardiovascular risk factors, subclinical carotid atherosclerosis and the ability of the Systematic Coronary Risk Estimation (SCORE) modified by European League Against Rheumatism (EULAR) to predict the high CV risk in our patients.

We included 50 patients followed for RA. These were 47 women and 03 men with a sex ratio of 0.06. The mean age was 44 years (+/− 12.37).

The mean duration of disease progression was 76.49 months (+/− 87.2) and the mean diagnostic delay was 38.27 (+/− 78.2).

Clinically, the mean number of painful joints was 5.6 (+/− 7.9) and the mean number of swollen joints was 5.02 (+/− 5.4). Joint deformities were noted in 66% of patients and extra-articular manifestations in 64% of cases.

The mean DAS-28 was 3.8 (+/− 1.2).

Anti-CCP was positive in 96.6% of patients and RF in 66.6% of cases. Clinical, immunological and therapeutic data are summarized in Table 1.

The frequency distribution of traditional cardiovascular risk factors was: hypertension (HT) (30%), diabetes-mellitus (6%), smoking (2%), no-exercise (22%), obesity (16%), metabolic syndrome (8%) (Table 2).

The distribution of the cardiovascular risk level by SCORE and mSCORE has been presented in Table 3. Fifty-eight percent had a low risk according to SCORE and mSCORE. Twenty-eight percent had moderate risk and eight percent had high risk acoording to mSCORE.

The mean cIMT was 0.63 mm (+/− 1.36). 10 patients (20%) had carotid atherosclerosis.

Eight patients (out of 14% or 51.7%) classified as moderate-risk according to mSCORE, were reclassified as high cardiovascular risk according to carotid ultrasound evaluation (gold-standard).

The sensitivity of the mSCORE equation in cardiovascular high-risk prediction was 20%, similar to the SCORE.

In the present study, only age (>45 years, p-value: 0.01) and hypertension (0.009) were correlated with carotid atherosclerosis (Table 4).

RA is the first chronic rheumatism in the general population [2] [23] [24]. This

DAS 28-CRP: disease activity score 28 with C-reactive protein; anti-CCP: anti-cyclic citrullinated peptides antibodies; DMARD: disease modifying anti-rheumatic drug.

DM: diabetes-mellitus; HT: Hypertension.

SCORE: Systematic coronary risk estimation; mSCORE: Systematic Coronary risk estimation modified by European league against rheumatism. *Diabetes-mellitus.

anti-CCP: anti-cyclic citrullinated peptides antibodies.

chronic inflammatory disease is associated with an increased risk of mortality, as compared with general population, mainly due to cardiovascular events [1] [3] - [16].

The mechanisms leading to accelerated atherosclerosis and increased rate of CV events are complex including traditional CV factors, systemic chronic inflammation; genetic compound; RA therapies such as corticosteroids [16] [25].

In the present study, we assessed the prevalence of carotid subclinical atherosclerosis and we found a lower prevalence when compared with other series. Ambrosino et al., reported a meta-analysis of 59 observational studies and showed an increased prevalence of atherosclerosis in RA patients with a prevalence of 32.7% [26]. Two studies were also especially conducted in sub-Saharan Africa about RA and subclinical atherosclerosis [9] [18]. They found also a high prevalence when compared with our study, 35.5% in black patients in South Africa and 32% in Kinshasa (Democratic Republic of Congo) [9] [18]. However, in Italia and India, the prevalence of subclinical atherosclerosis was slightly lower to this present study, respectively 16% and 15.2% [16] [17]. This could suggest differences due to environmental and genetic factors. Indeed, several studies have confirmed the role of genetic factors in the development of atherosclerosis in RA. Thus, alleles from the HLA-DRB1 genes especially the HLA-DRB1*0404 allele were associated with dysfunctional endothelial and presence of atheroma plaques [25] [27]. Other genes variants were also associated with cIMT in RA patients [4].

In the present study, the prevalence of atherosclerosis in RA patients was higher than expected frequency. In the Senegalese general population, the prevalence of subclinical atherosclerosis was estimated at 6.8% [28].

Atherogenesis in RA is mediated by traditional CV risk factors and disease related factors particularly high-grade inflammation, disease duration or RA therapies such as corticosteroids. One of the important finding of our study was the results about relations between subclinical atherosclerosis in RA patients and these traditional CV risk factors and disease specific factors. In the present study, only age (>45 years) and HT was correlated to carotid atherosclerosis. Several studies have demonstrated the impact of age in the genesis and development of atherosclerosis [18]. Age plays a role in the appearance of vascular lesions induced by oxidative stress and inflammation. These lesions can lead to the development of atherosclerosis also other CV risk factors such as HT [18]. HT was the most important CV risk factor associated with RA in our study as well as in South Africa [11]. An increased prevalence of HT was also reported in black patients without RA in sub-Saharan Africa [11]. Mulumba et al., reported also an association with older age and HT [18]. Ruscitti et al., showed also a correlation between atherosclerosis and HT [16]. Despite the well-known implication of other CV risk factors such as diabetes-mellitus, smoking, dyslipidemia, or metabolic syndrome, our study failed to demonstrate the expected association among these factors and subclinical atherosclerosis. Additionally, any RA-related factor was associated with carotid atherosclerosis, including disease-duration, disease-activity or joint-deformities. This suggests that our study had potentially limited power to identify significant statistic association between these factors and subclinical atherosclerosis.

Adequate stratification of CV risk is an important step in the management of RA patients [22]. Therefore, we evaluated the ability of the mSCORE in the prediction of the high-CV risk in comparison with carotid ultrasound. Indeed, previous studies have confirmed that a cIMT > 0.90 mm is indicative of atherosclerosis and increased of CV disease [22]. Carotid plaques are also predictors of coronary artery disease progression and closely associated with coronary artery disease [22]. We showed in this present study that the sensitivity of the mSCORE in the prediction of high risk was low, and the CV risk was underestimated by mSCORE in patient with RA. These results corroborate those of Corrales et al. [22]. However, there are differences in the determination. Corrales et al. followed the 2009 EULAR recommendations for CV risk management which suggested a multiplication factor 1.5 to calculated total CV disease risk (SCORE) if the patient fulfilled certain disease-specific criteria (i.e. disease duration of >10 years, RF or ACPA positivity and the presence of certain extra-articular manifestations) [22] [29]. In our study, mSCORE was obtained after application of the multiplication factor 1.5 in all RA patients according to the 2015/2016 update EULAR guidelines [21].

The main limitations of our study were the cross-sectional design without controls subjects and his small sample size. We did not perform a power analysis prior to the initiation of the study. The sample size was retained according to the limits of means of explorations. However, it’s the first study who described the frequency of subclinical atherosclerosis in Senegalese patients with RA. Carotid ultrasound should be proposed for a best CV risk assessment especially in RA patients with moderate CV risk.

In conclusion, this study showed a prevalence (20%) of subclinical carotid atherosclerosis in black Senegalese patients with RA higher than expected frequency in comparison with the prevalence in Senegalese general population.

We found also a correlation between HT and age (>45 years) and subclinical atherosclerosis, which highlights the importance of the evaluation of traditional CV risk factors in the management of RA.

We showed also, that CV risk was underestimated by mSCORE and the importance of carotid ultrasound for an appropriate stratification of the risk.

However, further studies are needed in sub-Saharan Africa, to evaluate other potential factors such as disease-specific factors that may be induced premature atherosclerosis in patients with RA.

Written informed consent for publication was obtained from the patients.

The authors declare that they have not received another source of funding.

The authors declare that they have no competing interests.

Sy Kane, B., Ndao, A.C., Samba, A., Ka, M.M., Sow, M., Aw, F., Dieng, M., Ndongo, S., Ndiaye, M.B., Diao, M. and Pouye, A. (2020) Cardiovascular Risk and Subclinical Atherosclerosis in Senegalese Patients with Rheumatoid Arthritis: A Cross-Sectional Study in a Single Centre. World Journal of Cardiovascular Diseases, 10, 1-11. https://doi.org/10.4236/wjcd.2020.101001